Enanta Pharmaceuticals (ENTA) vs Fennec Pharmaceuticals (FENC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Fennec Pharmaceuticals (FENC) has outperformed Enanta Pharmaceuticals (ENTA) over the past year, gaining 14.8% versus a gain of 7.1%. Over five years, FENC leads with a +16.5% price change compared with -83.1% for ENTA. Fennec Pharmaceuticals is the larger company by market cap ($375.6 million vs $364.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENTA | FENC |
|---|---|---|
| Share price | $12.50 | $10.71 |
| Market cap | $364.07M | $375.57M |
| 1-day change | +3.31% | +0.75% |
| YTD return | -23.27% | +39.09% |
| 1-year return | +7.08% | +14.79% |
| 5-year return | -83.07% | +16.54% |
| Forward P/E | — | 11.30 |
| EPS (TTM) | $-2.42 | $-0.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.15 | $13.25 |
| 52-week low | $10.20 | $5.65 |
| Distance from 52-week high | -27.11% | -19.17% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +74.64% | +64.99% |
| Average volume | 228.45K | 193.45K |
| Shares outstanding | 29.13M | 35.07M |
| Employees | 120 | 35 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Enanta Pharmaceuticals
ENTA stock →Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees
About Fennec Pharmaceuticals
FENC stock →Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
ENTA vs FENC FAQ
Which is bigger, Enanta Pharmaceuticals or Fennec Pharmaceuticals?
Fennec Pharmaceuticals (FENC) is larger, with a market capitalization of $375.57M compared with $364.07M for Enanta Pharmaceuticals (ENTA).
Which stock has performed better over the past year, ENTA or FENC?
FENC returned +14.79% over the past 12 months, compared with +7.08% for ENTA (price return, excluding dividends). Past performance does not predict future results.
Are Enanta Pharmaceuticals and Fennec Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Enanta Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for Fennec Pharmaceuticals.